Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
B GökeS Dejager

Abstract

The present study was a 52-week extension of a previously published, multi-center, randomized, parallel-group study. The aim of this extension study was to compare the efficacy and tolerability of vildagliptin and metformin in drug-naïve patients with type 2 diabetes over 104 weeks. The extension population comprised 305 patients randomized to vildagliptin (100 mg daily) and 158 patients randomized to metformin (2 000 mg daily). Pioglitazone was added as rescue medication if fasting glucose was >10 mmol/l; data from patients receiving rescue medication were excluded from the primary analysis. Baseline HbA (1c) averaged 8.4+/-0.1% in patients randomized to vildagliptin and 8.8+/-0.1% in those randomized to metformin. The adjusted mean change from baseline to study endpoint was -1.0+/-0.1% in vildagliptin-treated patients and -1.5+/-0.1% in those receiving metformin (p<0.001 vs. vildagliptin). These results were similar to those reported after the 1-year core phase of the study. The adjusted mean changes in body weight from baseline to endpoint were 0.5+/-0.4 kg and -2.5+/-0.5 kg in the vildagliptin and metformin groups, respectively. One or more adverse event (AE) was reported by 82.2% of patients receiving vildagliptin and by 8...Continue Reading

Citations

Mar 17, 2009·Advances in Therapy·Abd A TahraniAnthony H Barnett
May 16, 2009·Advances in Therapy·Carolyn F Deacon, Jens J Holst
Dec 1, 2011·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sylvie Dejager, Anja Schweizer
Jan 5, 2011·Diabetes, Obesity & Metabolism·B Charbonnel, B Cariou
Mar 21, 2012·Diabetes, Obesity & Metabolism·M A Nauck
May 14, 2010·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·James N Baraniuk, Mary J Jamieson
Jan 1, 2010·Drug, Healthcare and Patient Safety·Mary Elizabeth CoxJennifer B Green
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Radha AndukuriMarc Rendell
Jun 5, 2012·Vascular Health and Risk Management·Sylvie DejagerJames E Foley
Feb 5, 2013·Vascular Health and Risk Management·Valentina LukashevichWolfgang Kothny
May 14, 2009·Vascular Health and Risk Management·Carolyn F Deacon
Apr 15, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Dominique SimonSylvie Dejager
May 30, 2009·Acta Diabetologica·Stephan F E Praet, Luc J C van Loon
Feb 3, 2012·Expert Opinion on Pharmacotherapy·Marc RendellRadha Andukuri
Feb 20, 2014·Expert Opinion on Drug Metabolism & Toxicology·Stephanie A SteinStephen N Davis
Jun 23, 2009·Expert Opinion on Drug Safety·Joanna Mitri, Osama Hamdy
Aug 15, 2009·Expert Opinion on Investigational Drugs·Kjetil Retterstøl
Nov 11, 2011·Clinical Therapeutics·Kathleen R RichardJulienne K Kirk
Mar 8, 2011·Revista clínica española·E Menéndez TorreUNKNOWN Sociedad Española de Diabetes
Mar 1, 2011·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Edelmiro Menéndez TorreRamón Romero González
Sep 12, 2015·Journal of Diabetes and Metabolic Disorders·M P YavropoulouJ G Yovos
Apr 15, 2016·Science Translational Medicine·Hui WangHongting Zheng
Nov 13, 2009·Diabetes Care·Michael A NauckSten Madsbad
Jun 6, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Wlodzimierz M KolaczynskiMassoud Toussi
Nov 27, 2009·Postgraduate Medicine·Anna I PalalauAnthony H Barnett
Nov 26, 2009·Pharmacology & Therapeutics·Abd A TahraniAnthony H Barnett
May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Antonio R ChacraUNKNOWN CV181040 Investigators
Feb 27, 2013·Diabetes & Metabolism Journal·Jun Sung Moon, Kyu Chang Won
Oct 31, 2009·Expert Opinion on Pharmacotherapy·Moulinath BanerjeeHandrean Soran

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.